已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial

医学 头孢曲松 临床终点 冲程(发动机) 改良兰金量表 随机对照试验 临床试验 外科 抗生素 内科学 儿科 缺血性中风 缺血 工程类 微生物学 生物 机械工程
作者
Willeke F. Westendorp,Jan‐Dirk Vermeij,Elles Zock,Imke Hooijenga,Nyika D. Kruyt,Hans J L W Bosboom,Vincent I.H. Kwa,Martijn Weisfelt,Michel Remmers,R. ten Houten,A.H.C.M.L. Schreuder,Sarah E. Vermeer,Ewout J. van Dijk,Diederik W.J. Dippel,Marcel G. W. Dijkgraaf,Lodewijk Spanjaard,Marinus Vermeulen,Tom van der Poll,Jan M. Prins,Frédérique H Vermeij
出处
期刊:The Lancet [Elsevier BV]
卷期号:385 (9977): 1519-1526 被引量:323
标识
DOI:10.1016/s0140-6736(14)62456-9
摘要

Background In adults with acute stroke, infections occur commonly and are associated with an unfavourable functional outcome. In the Preventive Antibiotics in Stroke Study (PASS) we aimed to establish whether or not preventive antimicrobial therapy with a third-generation cephalosporin, ceftriaxone, improves functional outcome in patients with acute stroke. Methods In this multicentre, randomised, open-label trial with masked endpoint assessment, patients with acute stroke were randomly assigned to intravenous ceftriaxone at a dose of 2 g, given every 24 h intravenously for 4 days, in addition to stroke unit care, or standard stroke unit care without preventive antimicrobial therapy; assignments were made within 24 h after symptom onset. The primary endpoint was functional outcome at 3 months, defined according to the modified Rankin Scale and analysed by intention to treat. The primary analysis was by ordinal regression of the primary outcome. Secondary outcomes included death, infection rates, antimicrobial use, and length of hospital stay. Participants and caregivers were aware of treatment allocation but assessors of outcome were masked to group assignment. This trial is registered with controlled-trials.com, number ISRCTN66140176. Findings Between July 6, 2010, and March 23, 2014, a total of 2550 patients from 30 sites in the Netherlands, including academic and non-academic medical centres, were randomly assigned to the two treatment groups: 1275 patients to ceftriaxone and 1275 patients to standard treatment (control group). 12 patients (seven in the ceftriaxone group and five in the control group) withdrew consent immediately after randomisation, leaving 2538 patients available for the intention-to-treat-analysis (1268 in the ceftriaxone group and 1270 in the control group). 2514 (99%) of 2538 patients (1257 in each group) completed 3-month follow-up. Preventive ceftriaxone did not affect the distribution of functional outcome scores on the modified Rankin Scale at 3 months (adjusted common odds ratio 0·95 [95% CI 0·82–1·09], p=0·46). Preventive ceftriaxone did not result in an increased occurrence of adverse events. Overgrowth infection with Clostridium difficile occurred in two patients (<1%) in the ceftriaxone group and none in the control group. Interpretation Preventive ceftriaxone does not improve functional outcome at 3 months in adults with acute stroke. The results of our trial do not support the use of preventive antibiotics in adults with acute stroke. Funding Netherlands Organization for Health Research and Development, Netherlands Heart Foundation, and the European Research Council.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
猫猫完成签到 ,获得积分10
1秒前
小李完成签到 ,获得积分10
1秒前
淡然雁易完成签到 ,获得积分10
1秒前
cheqi完成签到 ,获得积分10
2秒前
甜甜的小土豆完成签到,获得积分10
3秒前
lynyee发布了新的文献求助10
3秒前
xixi完成签到,获得积分10
4秒前
乔木完成签到 ,获得积分10
4秒前
hkh发布了新的文献求助10
4秒前
samantha发布了新的文献求助20
5秒前
么么哒荼蘼酱完成签到,获得积分10
6秒前
张西畅完成签到 ,获得积分10
6秒前
6秒前
orixero的应助被李林采纳,获得20
6秒前
高贵碧凡完成签到 ,获得积分10
6秒前
Junex完成签到,获得积分10
7秒前
机智若云完成签到,获得积分0
7秒前
白门小强完成签到,获得积分10
7秒前
DoyoUdo完成签到 ,获得积分10
8秒前
汪鸡毛完成签到 ,获得积分0
8秒前
渔渔完成签到 ,获得积分10
8秒前
9秒前
冷艳的盼芙完成签到,获得积分10
9秒前
骑猪看月完成签到,获得积分10
9秒前
庚辰梦秋完成签到,获得积分10
9秒前
film完成签到 ,获得积分10
9秒前
月上云收完成签到,获得积分10
9秒前
2300755412完成签到,获得积分10
9秒前
云淡风轻一宝完成签到,获得积分10
10秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
10秒前
SciGPT的应助被科研通管家采纳,获得10
10秒前
qingche完成签到,获得积分10
10秒前
今后的应助被科研通管家采纳,获得10
10秒前
LingtonYou完成签到 ,获得积分10
10秒前
molihuakai的应助被科研通管家采纳,获得10
10秒前
10秒前
10秒前
ding的应助被科研通管家采纳,获得10
10秒前
11秒前
深情的迎海完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194810
求助须知:如何正确求助?哪些是违规求助? 9580525
关于积分的说明 21871483
捐赠科研通 7794329
什么是DOI,文献DOI怎么找? 3437718
关于科研通互助平台的介绍 2561095
邀请新用户注册赠送积分活动 2484446

今日热心研友

影月cindy
4 40
AireenBeryl531
40
温暖忆山
4
888
30
注:热心度 = 本日应助数 + 本日被采纳获取积分÷10